Clin2
NCT06304441Possibly a fitRecruiting

Pemetrexed plus lung cancer pill for brain metastasis

Leptomeningeal Metastasis

Treatments studied

Part of Brain & nervous system, Cancer clinical trials.

This trial tests if adding an injected chemotherapy drug (pemetrexed) to a targeted oral pill (like osimertinib) works better than the pill alone for patients with lung cancer that has spread to the brain and spinal cord lining.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
100 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • Be 18 to 75 years old
  • Have a specific type of lung cancer (NSCLC) with an EGFR mutation (L858R or Exon19Del)
  • Have cancer that has spread to the brain and spinal cord lining (leptomeningeal metastasis)
  • Have normal liver and kidney function and adequate blood cell counts
  • No history of severe nervous system disorders
  • No other rapidly spreading cancers that are not being treated

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06296745Recruiting· Phase 2
Pemetrexed in spinal fluid for lung cancer that spread to brain lining

This trial tests a drug called pemetrexed, given directly into the fluid around the spinal cord (intrathecal), for people with lung cancer that has spread to the brain and spinal cord lining and is no longer controlled by the targeted therapy osimertinib.

Huizhou, Guangdong
NCT06399926Recruiting
Pemetrexed via Ommaya for lung cancer in brain lining

This study tests whether a drug called pemetrexed, given directly into the fluid around your brain through a small implanted device, is safe and effective for treating lung cancer that has spread to the lining of the brain. It is for people whose cancer has a specific genetic change (EGFR, ALK, or ROS1) and who have already tried standard targeted pills that no longer control their disease.

Changsha, Hunan
NCT05805631Recruiting· Phase 2
Pemetrexed into spinal fluid for EGFR-mutant lung cancer spread to brain lining

This Phase 2 trial tests giving pemetrexed directly into the spinal fluid to treat cancer that has spread to the brain’s and spinal cord’s lining (leptomeningeal metastasis). It is for people with EGFR-mutant non-squamous lung cancer whose disease progressed after osimertinib, and who may benefit from a targeted treatment delivered to the area affected in the brain lining.

Taipei, Taiwan
NCT06441045Not yet recruiting· Phase 2
Higher dose of EGFR drug plus spinal chemotherapy for NSCLC with leptomeningeal progression

This trial tests if giving a higher dose of a third-generation EGFR-targeted pill (like osimertinib) along with chemotherapy injected into the spinal fluid can help people with advanced lung cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastases) after standard doses stopped working. The goal is to see if this combination works better than just the higher dose of the pill alone.

Fuzhou, Fujian
NCT07092202Recruiting· Phase 4
Firmonertinib and spinal injection for EGFR lung cancer with spread to brain lining

This trial tests combining a targeted pill (firmonertinib) with medication injected into the fluid around the spine for people with a specific type of lung cancer that has spread to the lining of the brain. It may offer a new option if you have already tried other EGFR drugs and are still having progression.

Wuhan, Hubei
NCT06901817Recruiting· Phase 2
Study of pemetrexed plus nivolumab for lung cancer that has spread to the lining of the brain

This trial tests a combination of two drugs, pemetrexed and nivolumab, given directly into the fluid around the brain and spinal cord. It is for people with a specific type of lung cancer (non-squamous non-small cell) that has spread to the lining of the brain and has not responded to other treatments.

Shanghai, Shanghai Municipality

Hear when a new Leptomeningeal Metastasis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.